Experimental combo targets stomach cancer fluid after other treatments fail
NCT ID NCT07196540
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a three-part treatment for people with advanced digestive tract cancers that have caused fluid buildup in the belly (malignant ascites) and haven't responded to standard therapies. The treatment combines low-dose radiation to the abdomen with two injected drugs: a modified tumor necrosis factor and an immunotherapy called tislelizumab. The goal is to see if this combination can shrink or stop the fluid buildup, and how safe it is. About 78 adults will take part in this early-phase trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant modified human tumor necrosis factor (rmhTNF-NC) combined with tislelizumab and radiotherapy
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced digestive tract cancers who have run out of standard therapies and are suffering from fluid buildup in the abdomen.
- What could go wrong
- This is an early Phase 2 trial with only 78 participants, so results may not apply to everyone. The combination therapy may cause side effects like inflammation or organ damage, and it's not yet known if it will meaningfully extend life or just temporarily reduce fluid.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGESTIVE SYSTEM NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- New combo therapy aims to stop liver cancer from coming back
- New hope for advanced colon cancer: which drug combo works best?
- New combo therapy aims to shrink untreatable liver tumors
- Heat therapy via endoscope tested for abdominal tumors
- Simple screening tool may catch muscle loss early in GI cancer patients